Olanzapine treatment in patients with typical and atypical neuroleptic-associated agranulocytosis

Int Clin Psychopharmacol. 1998 May;13(3):133-5. doi: 10.1097/00004850-199805000-00007.

Abstract

Two cases are reported of patients who developed agranulocytosis after treatment with typical and atypical antipsychotics. The patients were successfully treated with olanzapine. We suggest the consideration of olanzapine as a safer treatment in patients who require immediate continuation of antipsychotic medication and have a prior history of classic and atypical neuroleptic-induced agranulocytosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Agranulocytosis / chemically induced*
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Clopenthixol / adverse effects*
  • Clopenthixol / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Humans
  • Leukocyte Count / drug effects
  • Male
  • Olanzapine
  • Pirenzepine / adverse effects
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / therapeutic use
  • Risperidone / adverse effects*
  • Risperidone / therapeutic use
  • Schizophrenia, Paranoid / diagnosis
  • Schizophrenia, Paranoid / drug therapy*
  • Schizophrenia, Paranoid / psychology

Substances

  • Antipsychotic Agents
  • Benzodiazepines
  • Pirenzepine
  • Clopenthixol
  • Risperidone
  • Olanzapine